Your browser doesn't support javascript.
loading
Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination.
Yamamoto, Shinya; Yamayoshi, Seiya; Ito, Mutsumi; Sakai-Tagawa, Yuko; Nakachi, Ichiro; Baba, Rie; Kamimoto, Shigenobu; Ogura, Takayuki; Hagiwara, Shigehiro; Kato, Hideaki; Nakajima, Hideaki; Uwamino, Yoshifumi; Yagi, Kazuma; Sugaya, Norio; Nagai, Hiroyuki; Saito, Makoto; Adachi, Eisuke; Koga, Michiko; Tsutsumi, Takeya; Duong, Calvin; Okuda, Moe; Murakami, Jurika; Furusawa, Yuri; Ujie, Michiko; Iwatsuki-Horimoto, Kiyoko; Yotsuyanagi, Hiroshi; Kawaoka, Yoshihiro.
Affiliation
  • Yamamoto S; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Yamayoshi S; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Ito M; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Sakai-Tagawa Y; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo 162-8655, Japan.
  • Nakachi I; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Baba R; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Kamimoto S; Pulmonary Division, Department of Internal Medicine, Saiseikai Utsunomiya Hospital, Tochigi 321-0974, Japan.
  • Ogura T; Pulmonary Division, Department of Internal Medicine, Saiseikai Utsunomiya Hospital, Tochigi 321-0974, Japan.
  • Hagiwara S; Pulmonary Division, Department of Internal Medicine, Saiseikai Utsunomiya Hospital, Tochigi 321-0974, Japan.
  • Kato H; Department of Emergency and Intensive Care, Saiseikai Utsunomiya Hospital, Tochigi 321-0974, Japan.
  • Nakajima H; Department of Clinical Laboratory, Saiseikai Utsunomiya Hospital, Tochigi 321-0974, Japan.
  • Uwamino Y; Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Kanagawa 236-0004, Japan.
  • Yagi K; Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Kanagawa 236-0004, Japan.
  • Sugaya N; Department of Laboratory Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Nagai H; Department of Pulmonary Medicine, Keiyu Hospital, Kanagawa 220-8521, Japan.
  • Saito M; Department of Pediatrics, Keiyu Hospital, Kanagawa 220-8521, Japan.
  • Adachi E; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Koga M; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Tsutsumi T; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Duong C; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Okuda M; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Murakami J; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Furusawa Y; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Ujie M; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Iwatsuki-Horimoto K; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Yotsuyanagi H; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Kawaoka Y; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
iScience ; 26(7): 107208, 2023 Jul 21.
Article in En | MEDLINE | ID: mdl-37448563
ABSTRACT
SARS-CoV-2 has gradually acquired amino acid substitutions in its S protein that reduce the potency of neutralizing antibodies, leading to decreased vaccine efficacy. Here, we attempted to obtain mutant viruses by passaging SARS-CoV-2 in the presence of plasma samples from convalescent patients or vaccinees to determine which amino acid substitutions affect the antigenicity of SARS-CoV-2. Several amino acid substitutions in the S2 region, as well as the N-terminal domain (NTD) and receptor-binding domain (RBD), affected the neutralization potency of plasma samples collected from vaccinees, indicating that amino acid substitutions in the S2 region as well as those in the NTD and RBD affect neutralization by vaccine-induced antibodies. Furthermore, the neutralizing potency of vaccinee plasma samples against mutant viruses we obtained or circulating viruses differed among individuals. These findings suggest that genetic backgrounds of vaccinees influence the recognition of neutralizing epitopes.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: IScience Year: 2023 Document type: Article Affiliation country: Japón
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: IScience Year: 2023 Document type: Article Affiliation country: Japón